Conditions: Schizophrenia
Keywords: schizophrenia acute exacerbation inpatient
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 259
Healthy volunteers: no

Brief summary:
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: PF-02545920 intervention 2: PF-02545920 intervention 3: Placebo intervention 4: Risperidone
Intervention descriptions: intervention 1: 5 mg tablet every 12 hours for 28 days intervention 2: 15 mg tablet every 12 hours for 28 days intervention 3: One tablet/capsule every 12 hours for 28 days intervention 4: 3 mg capsule every 12 hours for 28 days

Protocol document: